- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 172 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| 27.03. | Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69 | 3 | Seeking Alpha | ||
| 27.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Intensity Therapeutics erhält neues US-Patent für Krebstherapie | 3 | Investing.com Deutsch | ||
| 23.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause | 3 | Benzinga.com | ||
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 245 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.03. | Intensity Therapeutics reports early trial data in breast cancer | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics erfüllt wieder NASDAQ-Anforderungen | 10 | Investing.com Deutsch | ||
| 06.03. | Intensity Therapeutics regains Nasdaq compliance | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement | 2 | Seeking Alpha | ||
| 06.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 190 | PR Newswire | SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company... ► Artikel lesen | |
| 05.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.02. | Intensity Therapeutics announces 1-for-25 reverse stock split | 21 | Investing.com | ||
| 13.02. | Intensity Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:25 an | 4 | Investing.com Deutsch | ||
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 267 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 23.01. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 13.01. | Intensity Therapeutics legt nach klinischer Validierung Strategie für 2026 fest | 6 | Investing.com Deutsch | ||
| 13.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 283 | PR Newswire | Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/... ► Artikel lesen | |
| 05.12.25 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 13 | Seeking Alpha |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| CRISPR THERAPEUTICS | 43,400 | +4,25 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| EDITAS MEDICINE | 2,470 | -0,40 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,720 | +0,12 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business | Ginkgo provides an update on its fourth quarter financial results
BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| NOVOCURE | 10,630 | -0,23 % | Novocure to Report First Quarter 2026 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,013 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,33 % bei einem Aktienkurs von 5,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.